Epizyme Announces Presentation at J.P. Morgan 35th

CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will present a company overview at the J.P. Morgan 35 ^th Annual Healthcare Conference on Monday, January 9, 2017 at 12:00 p.m. PT. The conference is taking place January 9-12, 2017 at the Westin St. Francis in San Francisco.

To access the live webcast of Epizyme’s presentation, please visit the Events & Presentations page within the Investor page of the website at www.epizyme.com . Replays of the webcast will be available on the Epizyme website for 90 days following the conference.

About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients. For more information, visit www.epizyme.com .

Media Contact: Julie DiCarlo, Epizyme, Inc. (617) 306-5823 jdicarlo@epizyme.com Investor Contact: Monique Allaire, THRUST Investor Relations (617) 895-9511 monique@thrustir.com